← Back
Data updated: Mar 29, 2026
AstraZeneca
AZN OncologyRespiratoryCardiovascular
Big Pharma
Anglo-Swedish pharma with strength in oncology, cardiovascular, and respiratory. Key drugs include Tagrisso, Farxiga, and Imfinzi. COVID-19 vaccine partner with Oxford.
$54.1B
Revenue (2024)
$220.0B
Market Cap
-
Trials
78
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 52%
7 drugs Phase 3: 124 Phase 2: 66 Phase 1: 109
Respiratory 25%
7 drugs Phase 3: 57 Phase 2: 27 Phase 1: 56
Cardiovascular 9%
5 drugs Phase 3: 15 Phase 2: 13 Phase 1: 22
Metabolic 7%
2 drugs Phase 3: 10 Phase 2: 14 Phase 1: 31
Immunology 6%
1 drugs Phase 3: 10 Phase 2: 11 Phase 1: 16
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology, Cardiovascular
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory
Active (35)
WAINUA (AUTOINJECTOR) TRUQAP BEYFORTUS SYMBICORT AEROSPHERE AIRSUPRA IMJUDO TEZSPIRE SAPHNELO BREZTRI AEROSPHERE KOSELUGO LOKELMA FASENRA CALQUENCE IMFINZI BEVESPI AEROSPHERE TAGRISSO LYNPARZA XIGDUO XR NEXIUM 24HR FARXIGA BRILINTA DALIRESP SYMBICORT BYETTA CRESTOR PRILOSEC OTC FASLODEX NEXIUM PULMICORT RESPULES ARIMIDEX CASODEX RHINOCORT PRILOSEC NALOXONE HYDROCHLORIDE XYLOCAINE W/ EPINEPHRINE
Discontinued (38)
FUROSEMIDE BYDUREON BCISE BYDUREON PEN BYDUREON XYLOCAINE ONGLYZA KOMBIGLYZE XR TENORMIN QTERN NEXIUM IV DROPERIDOL IRESSA QTERNMET XR SYMLIN BRETYLIUM TOSYLATE ZOMIG-ZMT EMLA EPANOVA AQUASOL A PLENDIL NOLVADEX LEXXEL PULMICORT NEUTREXIN METAPROTERENOL SULFATE ELAVIL TONOCARD CITANEST PLAIN CITANEST CITANEST FORTE XYLOCAINE 5% W/ GLUCOSE 7.5% DURANEST SORBITRATE ISOETHARINE HYDROCHLORIDE FENTANYL CITRATE AND DROPERIDOL YUTOPAR DYCLONE DALGAN
Company Info
- First Approval
- 1951-05-17
- Latest
- 2026-02-19
- Applications
- 103
FDA Sponsor Names
ASTRAZENECAASTRAZENECA LPASTRAZENECA ABMEDIMMUNE ONCOLOGYASTRAZENECA PHARMS +1